領航醫藥生物科技(00399.HK)擬收購Conflux資產
格隆匯6月30日丨領航醫藥生物科技(00399.HK)宣佈,於2025年6月30日,公司(作爲買方)已與賣方及Conflux訂立諒解備忘錄,內容有關收購目標公司全部股權的潛在收購事項,前提爲目標公司按照與公司的協議完成收購Conflux資產。
Conflux爲一間於香港註冊成立的有限公司,主要從事開發區塊鏈技術。於本公告日期,執行董事伍鳴博士亦爲Conflux的董事及Conflux的唯一最終實益擁有人。
目標公司爲一間將由賣方在開曼羣島註冊成立並由賣方全資擁有的有限公司。
公司正積極發掘新商機,令收益來源多元化,並實施策略計劃以提升表現,且公司擬擴充業務至區塊鏈技術,進軍數碼創新行業。訂立諒解備忘錄表明公司致力透過潛在收購事項進軍數碼創新行業,以發展此新業務分部。公司認爲此舉不但可令集團業務更多元化,亦可爲集團帶來新溢利增長動力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.